Anne Sullivan joins Prilenia Therapeutics as Chief Business Officer

Prilenia Therapeutics B.V. has announced the appointment of Anne Sullivan as Chief Business Officer.

Sullivan will lead all strategic collaboration activities at the clinical stage biotechnology company, which develops novel therapeutics to slow the progression of neurodegenerative and neurodevelopmental disorders.

Dr Michael R. Hayden, CEO and Founder of Prilenia, said:

“As Prilenia prepares for key milestones in its pipeline over the coming months, we believe Anne brings tremendous experience and perspective to our leadership team.

“We are delighted to welcome Anne to the team and are confident that her strong background in neurology and expertise in corporate and business development will be invaluable as Prilenia takes important steps toward its future.”

Sullivan has more than 25 years of experience in the biopharmaceutical industry, previously serving as Chief Business Officer at Rodin Therapeutics.

She also held senior positions at Sea Pharmaceuticals and Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.).

Anne Sullivan, Chief Business Officer at Prilenia, said:

“Prilenia represents an organisation truly committed to scientific rigor as well as to people living with serious neurological diseases, like Huntington’s disease and ALS, and I couldn’t be more pleased to join the team and advance its mission.

“Prilenia is poised to make significant progress over the next few quarters, with the Company expecting key data from its ongoing studies of pridopidine in ALS and Huntington’s disease.

“Knowing that many people are waiting for potential new therapeutic options, we are actively evaluating opportunities to accelerate and expand the potential impact of pridopidine.”